Back to Search
Start Over
MYC overexpression is associated with an early disease progression from MDS to AML.
- Source :
-
Leukemia research [Leuk Res] 2021 Dec; Vol. 111, pp. 106733. Date of Electronic Publication: 2021 Oct 21. - Publication Year :
- 2021
-
Abstract
- Recent studies demonstrated that MYC epigenetically regulates AML cell survival and differentiation by suppressing IDH1/2-TET2-5hmC signaling and that MYC overexpression is associated with poor survival outcomes in multiple AML patient cohorts. However, the oncogenic roles of MYC in MDS remain to be explored. A total of 41 patients with de novo MDS were retrospectively identified using the Total Cancer Care database at the Moffitt Cancer Center. A total of 61 % of patients had low MYC expression and 39 % of patients had high MYC expression defined as MYC reactivity by immunohistochemical staining in ≥5% of bone marrow (BM) cells at the time of MDS diagnosis. The median MDS-to-AML progression free survival (PFS) was significantly shorter in the high MYC group (median PFS 9.3 vs. 17.7 months, HR = 2.328, p = 0.013). Further, overall survival (OS) was also shorter in the high MYC patients (median OS 19.7 vs. 51.7 months, HR = 2.299, p = 0.053). Multivariate analyses demonstrated that high MYC expression is an independent poor prognostic factor for the MDS-to-AML progression (HR = 2.275, p = 0.046). Our observations indicate that MYC may play a crucial role in MDS transformation to AML and the underlying mechanisms of MYC-driven MDS clonal expansion and leukemic transformation require further investigation.<br /> (Copyright © 2021 Elsevier Ltd. All rights reserved.)
- Subjects :
- Adult
Aged
Aged, 80 and over
Disease Progression
Female
Follow-Up Studies
Humans
Leukemia, Myeloid, Acute drug therapy
Leukemia, Myeloid, Acute genetics
Leukemia, Myeloid, Acute metabolism
Male
Middle Aged
Myelodysplastic Syndromes drug therapy
Myelodysplastic Syndromes genetics
Myelodysplastic Syndromes metabolism
Neoplasms, Second Primary drug therapy
Neoplasms, Second Primary genetics
Neoplasms, Second Primary metabolism
Prognosis
Proto-Oncogene Proteins c-myc genetics
Retrospective Studies
Survival Rate
Young Adult
Antineoplastic Combined Chemotherapy Protocols therapeutic use
Leukemia, Myeloid, Acute pathology
Mutation
Myelodysplastic Syndromes pathology
Neoplasms, Second Primary pathology
Proto-Oncogene Proteins c-myc metabolism
Subjects
Details
- Language :
- English
- ISSN :
- 1873-5835
- Volume :
- 111
- Database :
- MEDLINE
- Journal :
- Leukemia research
- Publication Type :
- Academic Journal
- Accession number :
- 34749168
- Full Text :
- https://doi.org/10.1016/j.leukres.2021.106733